Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Bolt Biotherapeutics Inc (BOLT)

22 + Investors. Track Smart Money conviction in BOLT. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +1
Streak
1Q ▲
Buyers last Q
61%

Smart Money Signals — BOLT

Based on 22 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds added BOLT than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🔻

Below peak — only 58% of 3.0Y high

58% of all-time peak
Only 22 funds hold BOLT today versus a peak of 38 funds at 2023 Q2 — just 58% of the maximum. Low institutional ownership can mean the stock is out of favor, but it also means there's a large pool of potential buyers if sentiment turns.
📉

Outflows — 21% fewer funds vs a year ago

fund count last 6Q
6 fewer hedge funds hold BOLT compared to a year ago (-21% decline). When institutions consistently reduce their exposure, it's worth exploring the underlying fundamental reasons driving them away.
🟢

More buyers than sellers — 61% buying

11 buying7 selling
Last quarter: 11 funds were net buyers (5 opened a brand new position + 6 added to an existing one). Only 7 were sellers (3 trimmed + 4 sold completely). A clear majority buying is a strong confirmation signal.
➡️

Steady new buyers — ~5 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 2 → 4 → 3 → 5. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔒

50% of holders stayed for 2+ years

■ 50% conviction (2yr+) ■ 23% medium ■ 27% new
11 out of 22 hedge funds have held BOLT for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💎

Buying through price weakness — shares +2%, value -24%

Value
-24%
Shares
+1%
Last quarter: funds added +2% more shares while total portfolio value only changed -24%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
➡️

Steady discovery — ~5 new funds/quarter

2 → 2 → 4 → 3 → 5 new funds/Q
New funds entering each quarter: 2 → 4 → 3 → 5. Consistent flow of new institutional buyers without clear acceleration or slowdown.
🏛️

Veteran-anchored — 59% veterans vs 27% newcomers

■ 59% veterans ■ 14% 1-2yr ■ 27% new
Entry-cohort mix of 22 holders: 13 (59%) are 2+ year veterans, 3 entered 1–2 years ago, and 6 (27%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
📋

Smaller funds dominant — 9% AUM from top-100

9% from top-100 AUM funds
6 of 22 holders rank in the top 100 by AUM, but together hold only 9% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
1.6
out of 10
Low Exit Risk
Exit risk score 1.6/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — BOLT

In 2026 Q1, 11 hedge funds were net buyers of BOLT (5 opened a new position, 6 added to an existing one), while 7 reduced or exited (3 trimmed, 4 sold completely) — a 61% buyer ratio, indicating clear institutional accumulation. Net fund flow last quarter: +1 funds (more new holders than closures). Total institutional holders: 22.

Hedge Fund Ownership: BOLT

How many hedge funds hold BOLT — quarterly history vs. share price
Quarterly hedge fund ownership of BOLT vs. share price

Market Analysis: BOLT

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: BOLT

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Bolt Biotherapeutics Inc (BOLT) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much BOLT has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 78d ago
BOLT
+9.7%
XLV
+3.8%

BOLT outperformed XLV by +5.9% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 33d ago
BOLT
-7.3%
XLV
+4.9%

Since the filing became public, BOLT outperformed XLV by -12.2% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

3 top-rated funds 0 high-conviction
Consensus
2.6
/ 10
breadth
×
Elite
0.1
/ 10
conviction
Hedge Fund Positioning: BOLT
22 + Investors

Track Smart Money conviction in BOLT. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 22 21 4.76%
13F Shares 613K 603K 1.77%
Total Value $2M $3M -24.49%
New Positions 5 3 +2
Increased Positions 6 4 +2
Closed Positions 4 6 -2
Reduced Positions 3 4 -1
Total Calls 0 0 -
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: BOLT

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

22 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in BOLT. Verified SEC 13F-HR filings.

QUARTER:
Top 21 BOLT holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 T3 Companies, LLC 0.20% 38,000 $154K
2 Nano Cap New Millennium Growth Fund L P 0.10% 27,500 $111K
3 Nan Fung Group Holdings Ltd 0.10% 29,250 $118K
4 Pivotal bioVenture Partners Investment Advisor LLC 0.06% 42,581 $172K
5 Pfizer Inc 0.06% 31,305 $137K
6 Vivo Capital, LLC 0.02% 72,414 $293K
7 Sofinnova Investments, Inc. 0.02% 137,721 $556K
8 Lynx1 Capital Management LP 0.02% 30,800 $124K
9 Board of Trustees of The Leland Stanford Junior University 0.02% 35,977 $145K
10 Shay Capital LLC 0.01% 14,905 $60K
11 Renaissance Technologies LLC 0.00% 77,225 $312K
12 Tower Research Capital LLC (TRC) 0.00% 1,093 $4K
13 Citadel Advisors LLC 0.00% 10,109 $41K
14 Susquehanna International Group, LLP 0.00% 11,657 $47K
15 Vanguard Fiduciary Trust Co 0.00% 3,095 $13K
16 SBI Securities Co., Ltd. 0.00% 10 —
17 Morgan Stanley 0.00% 3,189 $13K
18 Vanguard Capital Management LLC 0.00% 7,060 $29K
19 BlackRock, Inc. 0.00% 9,711 $39K
20 UBS Group AG 0.00% 787 $3K
21 Barclays plc 0.00% 6 —
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Bolt Biotherapeutics Inc (BOLT)

What does the Smart Money Trend signal show for BOLT?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added BOLT than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for BOLT?

More buyers than sellers — 61% buying: Last quarter: 11 funds were net buyers (5 opened a brand new position + 6 added to an existing one). Only 7 were sellers (3 trimmed + 4 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for BOLT holders?

Smaller funds dominant — 9% AUM from top-100: 6 of 22 holders rank in the top 100 by AUM, but together hold only 9% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held BOLT?

50% of holders stayed for 2+ years: 11 out of 22 hedge funds have held BOLT for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Bolt Biotherapeutics Inc (BOLT) following the 2026 Q1 hedge fund 13F filings?

As of today, BOLT has moved -7.3% since the 2026 Q1 13F filing date (May 15, 2026), compared to +4.9% for the XLV sector ETF — an outperformance of -12.2%. Since the quarter end (March 31, 2026), BOLT has gained +9.7% vs +3.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →